diabetestalk.net

Medtronic Intellis Review

Medtronic Enrolls First Patient In Pain Study To Assess Optimized Spinal Cord Stimulation Programming

Medtronic Enrolls First Patient In Pain Study To Assess Optimized Spinal Cord Stimulation Programming

Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment DUBLIN - January 9, 2018 - Medtronic plc (NYSE: MDT ) today announced the first patient enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are undergoing spinal cord stimulation (SCS) treatment managed with the EvolveSM workflow*, which standardizes guidance that balances high-dose (HD) and low-dose (LD) therapy settings to help physicians optimize treatment. Evolve runs on Medtronic SCS systems including Intellis(TM), the world's smallest implantable SCS neurostimulator, which recently received U.S. Food and Drug Administration and CE Mark approval. The first patient was enrolled by The Center for Interventional Pain & Spine in Wilmington, Delaware. "Our goal is to improve or restore function. Even with all of today's technological advances, chronic pain can be challenging to manage; this is further complicated by the opioid crisis," said Michael Fishman, M.D., from The Center for Interventional Pain & Spine. "Standard treatment guidance has the potential to help optimize pain relief, and the Vectors Post Market study will provide valuable data about the efficacy of high dose stimulation using standardized programming through the Evolve workflow." The Vectors study is a prospective, multi-center, post-marketing study that will enroll up to 175 patients with chronic intractable pain of the low back and legs at up to 25 sites in the U.S. The study will assess SCS's long-term efficacy and impact on quality of life and was designed to provi Continue reading >>

Fda Approves Medtronic's Intellis Scs - Spinal News International

Fda Approves Medtronic's Intellis Scs - Spinal News International

US FDA approves Medtronics Intellis spinal cord stimulation device The US Food and Drug Administration has approved Medtronics Intellis spinal cord stimulator. The company has now launched the product in the USA for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance. It can power the Evolve workflow, which is intended to standardise guidance and balance high-dose (HD) and low-dose (LD) therapy settings. The Intellis platform can record and track patient activity 24/7, and is managed on the Samsung Galaxy Tab S2 tablet interface. The company reports that this enables physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients therapy needs. Duke University Medical Center in Durham, USA, is one of the first centres to implant a US patient with the Intellis device. Chronic pain is challenging to manage. Having real-time data can provide more information about patients quality of life changes, says Lance Roy, pain medicine specialist at Duke University Medical Center. This platform represents a welcome new option for managing some kinds of chronic pain. New non-opioid treatment options are important given the national crisis related to opioid abuse. Continue reading >>

Medtronic Intellis Implant

Medtronic Intellis Implant

Hi all - I had the new Medtronic Intellis SCS implanted a couple of weeks ago. This system was just launched earlier this month, so I'm probably one of the first patients to receive their latest technology. This is my second Medtronic SCS. The first was installed a couple of years ago, but failed a few months ago (turns out I had fractured both leads). I'm still early in my recovery, but the new system seems to be working okay. The Intellis rechargeable battery is much smaller than my old primary cell (non-rechargeable) battery, so is a lot more comfortable in my hip. The device rep was able to install my old programs on my new battery, although they then had to be modified to give me the same coverage due to the new lead placement.Unlike my old controller, the new controller is wireless, so I don't need to use an antenna to modify my settings. The new controller also has a touch screen, so the interface is a little more user friendly than the old system. I was a little worried about the added hassle of recharging, but so far this is not too bad. I'm recharging when I get down to 60-70% charge, which takes 15-20 minutes about every 3 days. Just wanted to share in case anybody else is looking at this system. Continue reading >>

Medtronic | Nevro Senza Vs. Medtronic | Medtech[y] Message Boards

Medtronic | Nevro Senza Vs. Medtronic | Medtech[y] Message Boards

How do we stop the slow bleed? These schmucks are everywhere. How do we stop the slow bleed? These schmucks are everywhere. The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit. Your email address will never be used for any other reason and will never be sold to email marketers. But what is the problem? Even staunch competitors seem to acknowledge that the product is legit. Nevro seems like it would be a great company to sell for. Why do they have trouble retaining talent But what is the problem? Even staunch competitors seem to acknowledge that the product is legit. Nevro seems like it would be a great company to sell for. Why do they have trouble retaining talent I am not with Nevro but we all know plenty of MDT reps that have gone over there in the last couple of years. The ones I keep in touch will all say your success (or lack of) depends on the quota you get. Nevro still acts like a startup and expects crazy growth and if you get a bad quota you could end up making very little money and that has driven some of these reps to leave before they are forced out. I am not with Nevro but we all know plenty of MDT reps that have gone over there in the last couple of years. The ones I keep in touch will all say your success (or lack of) depends on the quota you get. Nevro still acts like a startup and expects crazy growth and if you get a bad quota you could end up making very little money and that has driven some of these reps to leave before they are forced out. It will get wo Continue reading >>

Medtronic Reviews | Glassdoor

Medtronic Reviews | Glassdoor

I worked at Medtronic full-time(More than 3 years) Medtronic is one of the best companies to provide medical products in the world. They have great benefits and mostly good work ethics. I created an unparalleled method to test and diagnose issues for the development of a large scale medical device. During this process my group had mandatory Saturdays. Above and beyond that regularly worked from home after hours, Sundays etc. Upon time for annual review any and all negativity was pin pointed, over done, focused upon. All extra effort not even mentioned. Boss hired friends, relatives, friends of relatives, relatives of his boss, friends of his boss even if they were unqualified and all got great reviews. This man was eternally pissed off, would even shout "I'm pissed off" from his cubicle, I was reprimanded for being too happy. I was reprimanded for emailing my ex-boss. Couldn't look him in the eye after that and he eventually fired me from Senior VnV Engineer position then called the police after I quietly walked out. Avoid management configurations where co-workers from other companies populate management levels. Management knows everything already, they don't need advice. Flag as InappropriateFlag as Inappropriate Continue reading >>

Latest Stories Pain News Network

Latest Stories Pain News Network

The U.S. Food and Drug Administration has approved a new spinal cord stimulator developed by Medtronic that can be managed, tracked and updated remotely on a Samsung Galaxy tablet. The Intellis stimulator is designed for patients with chronic, intractable pain of the trunk and/or limbs. The Intellis platform can track patient activity 24/7 on the Samsung Galaxy Tab S2 tablet, enabling physicians to personalize the settings for individual patients and monitor their progress using Medtronics Evolve software system. "The launch of the Intellis platform isn't just about a new device, but about combining cutting edge hardware with optimal therapy through the Evolve workflow to enable personalized, long-term pain relief," said Marshall Stanton, MD, president of Medtronic's Pain Therapies division. The Intellis platform was designed based on what is most important to patients and physicians. We considered the entire patient journey - starting with the primary goal of optimal pain relief and access to important diagnostic tools, like MRI, to ease of use with simplified programming, faster recharge and a smaller implant." Spinal cord stimulators (SCS) are often considered the treatment of last resort for chronic back and leg pain, because the devices have to be surgically implanted near the spine and connected to batteries placed under the skin. The implants send electrical impulses into the spine to mask pain. Some patients find the stimulators ineffective and have them removed. According to one study, only about half of patients who received a traditional SCS device have a 50 percent reduction in their back and leg pain. New technologies are being developed to make the devices smaller, more effective and easier to recharge. Medtronic says Intellis is the world's smallest full Continue reading >>

Medtronic Wins Fda Nod For Intellis Scs, Launches In Us

Medtronic Wins Fda Nod For Intellis Scs, Launches In Us

Home Medtronic wins FDA nod for Intellis SCS, launches in US Medtronic wins FDA nod for Intellis SCS, launches in US Medtronic (NYSE: MDT ) said today it won FDA approval for its Intellis implantable spinal cord stimulation system and launched it in the US. The Fridley, Minn.-based company touted the newly revised system as the worlds smallest, and said that the new unit was designed to improve battery performance and standardize guidance and balancing of high-dose and low-dose therapy settings. Drawing upon our 40-year legacy in SCS, the launch of the Intellis platform isnt just about a new device, but about combining cutting edge hardware with optimal therapy through the Evolve workflow to enable personalized, long-term pain relief. Medtronic is committed to addressing patient needs, so the Intellis platform was designed based on what is most important to patients and physicians. We considered the entire patient journey starting with the primary goal of optimal pain relief and access to important diagnostic tools, like MRI, to ease of use with simplified programming, faster recharge and a smaller implant, Medtronic pain therapies division prez Dr. Marshall Stanton said in a press release. Medtronic said that the device is designed to interface with a Samsung Galaxy Tab S2 tablet interface to allow physicians to actively monitor and make modifications to the unit to meet patient needs. Chronic pain is challenging to manage. Having real-time data can provide more information about patients quality of life changes. This platform represents a welcome new option for managing some kinds of chronic pain. New non-opioid treatment options are important given the national crisis related to opioid abuse, Dr. Lance Roy of Duke University Medical Center, whi Continue reading >>

A Review Of Spinal Cord Stimulation Systems For Chronic Pain

A Review Of Spinal Cord Stimulation Systems For Chronic Pain

A review of spinal cord stimulation systems for chronic pain We are experimenting with display styles that make it easier to read articles in PMC. The ePub format uses eBook readers, which have several "ease of reading" features already built in. The ePub format is best viewed in the iBooks reader. You may notice problems with the display of certain parts of an article in other eReaders. Generating an ePub file may take a long time, please be patient. A review of spinal cord stimulation systems for chronic pain Paul Verrills, Chantelle Sinclair, and Adele Barnard Spinal cord stimulation (SCS) applications and technologies are fast advancing. New SCS technologies are being used increasingly in the clinical environment, but often there is a lag period between the clinical application and the publishing of high-quality evidence on safety and efficacy. Recent developments will undoubtedly expand the applicability of SCS, allowing more effective and individualized treatment for patients, and may have the potential to salvage patients who have previously failed neuromodulation. Already, high-level evidence exists for the safety, efficacy, and cost-effectiveness (Level III) of traditional SCS therapies in the treatment of chronic refractory low back with predominant limb pain (regardless of surgical history). More than half of all patients with chronic painful conditions experience sustained and significant levels of pain reduction following SCS treatment. Although only limited evidence exists for burst stimulation, there is now Level I evidence for both dorsal root ganglion SCS and high-frequency SCS that demonstrates compelling results compared with traditional therapies. The body of evidence built on traditional SCS research may be redundant, with newer iterations of SCS t Continue reading >>

Medtronic's Intellis Implantable Spinal Cord Stimulator Granted Ce Mark

Medtronic's Intellis Implantable Spinal Cord Stimulator Granted Ce Mark

Medtronic's Intellis Implantable Spinal Cord Stimulator Granted CE Mark Non-opioid alternative for chronic pain and offers personalized pain relief and advanced activity tracking. Intellis is the world's smallest fully implantable SCS neurostimulator. Image courtesy of Medtronic. European Interspinous Process Decompression Market to Surpass $30 Million by 2023 Medtronic plc announced that it received CE mark for the Intellis platform for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) as an aid in the management of certain types of chronic pain.* Intellis, the world's smallest fully implantable SCS neurostimulator, simplifies and improves the patient experience with improved battery performance that can power the Evolveworkflow,** which standardizes guidance and balances high-dose (HD) and low-dose (LD) SCS therapy settings. The Intellis platform is managed on the Samsung Galaxy Tab S2 tablet interface and can record and track patient activity 24/7. Intellis is now available in Europe and the United States. One in five adults in Western Europe suffers from chronic pain, a devastating condition with a costly personal and societal impact.1 Chronic pain can negatively impact all aspects of a person's liferelationships, work productivity and activities of daily living, yet it remains under-recognized and undertreated.1 Published studies have shown that when used by carefully selected patients with chronic pain, SCS may provide effective long-term pain relief, improved quality of life and pain-related disability, and may reduce the need for pain medications.2Similarly, PNS may also provide back pain relief, improvement in back pain-related disability, and reduce the need for pain medications.3-4The potential benefits of neurostimulation are critica Continue reading >>

Spinal Cord Stimulation Archives - Neuronews International

Spinal Cord Stimulation Archives - Neuronews International

Spinal cord stimulation and chronic pain: In the end its about... Krishnan Chakravarthy writes in NeuroNews about how spinal cord stimulation can be used to treat chronic pain and how this can help America overcome... Shuffle stimulation improves pain scores in pilot study A pilot study published in Neuromodulation: Technology at the Neural Interface suggests that high frequency stimulation (HFS), an alternative SCS waveform could also be... Medtronic has a long-standing commitment to deliveringinnovative pain stimulation technology and building the evidencethat matters today and leads us into the future.This is again... WHISPER SCS study: therapy optimisation associated with more effective pain relief New data from the WHISPER randomised controlled trial (RCT) have demonstrated that patients who are given the choice to use both sub-perception and paraesthesia-based... Spectra WaveWriter Spinal Cord Stimulator System receives FDA approval The Spectra WaveWriter Spinal Cord Stimulator (SCS) System (Boston Scientific) has received FDA approval. It is the first and only system approved by the... FDA approves Senza II Spinal Cord Stimulation System The US Food and Drug Administration has approved the next-generation Senza II Spinal Cord Stimulation (SCS) System (Nevro) delivering HF10 therapy.According to the company,... First patient enrolled in study to assess optimised spinal cord stimulation... The first patient has been enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are... Nevro receives CE mark for full-body MRI conditional labelling with the... Nevro has received the CE mark for full-body magnetic resonance imaging (MRI) conditional labelling on the Senza Spinal Cord Stimulation (SCS) System deliv Continue reading >>

Medtronic Launches Next-gen Spinal Cord Stimulator For Chronic Pain Management

Medtronic Launches Next-gen Spinal Cord Stimulator For Chronic Pain Management

Medtronic Launches Next-Gen Spinal Cord Stimulator for Chronic Pain Management Includes world's smallest implantable spinal cord stimulator; offers personalized pain relief and advanced activity tracking. Medtronic's Intellis Spinal Cord Stimulation Platform. Image courtesy of Medtronic. New 510(k) Approach Would Leverage FDA Objective Criteria Medtronic plc announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the EvolveSMworkflow, which standardizes guidance and balances high-dose (HD) and low-dose (LD) therapy settings. The Intellis platform can record and track patient activity 24/7 and is managed on the Samsung Galaxy Tab S2 tablet interface, enabling physicians to address the subjective and personal nature of chronic pain by monitoring progress and making modifications to better suit their patients' therapy needs. Duke University Medical Center in Durham, N.C. implanted one of the first patients in the U.S. with the Intellis device. "Chronic pain is challenging to manage. Having real-time data can provide more information about patients' quality of life changes," said Dr. Lance Roy, pain medicine specialist at Duke University Medical Center. "This platform represents a welcome new option for managing some kinds of chronic pain. New non-opioid treatment options are important given the national crisis related to opioid abuse." Back problems are one of the top 10 most expensive medical conditions, with an estimated 30 percent of the 300,000 patients annually that undergo lumbosacral spine procedures developing chronic intractable pain.1Chron Continue reading >>

Medtronic Pain Management Device Approved By Fda Blogmedical Device Blog

Medtronic Pain Management Device Approved By Fda Blogmedical Device Blog

Medtronic Pain Management Device Approved by FDA Medtronic announced FDA approval and U.S. launch of its Intellis Platform for the management of certain types of chronic intractable pain. According to Medtronic, the Intellis platform features the worlds smallest implantable spinal cord stimulator (SCS), which includes an implantable pulse generator that looks like an older-style pacemaker, but with wire leads that delivers mild current to a spinal vertebra. The Intellis, and other SCS systems deliver, neurostimulation at the spinal cords to prevent pain signals from reaching the brain. The MIT Technology Review reports that SCS systems carry promise because they represent an alternative to opioid-based pain management. It is estimated that more than 20,000 Americans a year die from overdoses of prescription pain drugs. Government and industry alike recognize the gravity of the opioid issue. FDA Commissioner Dr. Scott Gottlieb has stated that opioid abuse is is taking a staggering human and economic toll and is therefore a top priority. Industries are also responding with ever-improving SCS systems (Medtronics pain-therapies business show $825 million in revenue during the companys 2017 fiscal year). According to Medtronic , the Intellis system allows physicians to better address the subjective and personal nature of patients chronic pain. Based on recorded and tracked patient activity, including body positions and how patients self-administer their therapy , Intellis allows a physician to program and manage pain therapy for each patient with a wirelessly connected Samsung tablet. Continue reading >>

Medtronic Secures Fda Approval For Intellis Spinal Cord Stimulator

Medtronic Secures Fda Approval For Intellis Spinal Cord Stimulator

Medtronic secures FDA approval for Intellis spinal cord stimulator MDBR Staff Writer Published 20 September 2017 Medtronic has secured the US Food and Drug Administration (FDA) approval for its next generation spinal cord stimulator branded as Intellis platform for the management of certain forms of chronic intractable pain. Following the approval, the Irish medical device company has launched Intellis platform in the US which it says features the smallest implantable spinal cord stimulator in the world. According to Medtronic, the Intellis platform can optimize treatment and facilitate better patient-physician communication by monitoring and sharing daily activities, body positions and therapy usage while providing physicians an objective look at the patients mobility and progress. The Intellis platform was designed to address shortcomings like battery performance with existing spinal cord stimulation (SCS) systems. Medtronic says that the battery performance issue has been addressed through its Overdrive battery technology which enables the battery to be 100% recharged from empty to full in nearly 60 minutes. The Intellis platform can also power the Evolve workflow and can record and track patient activity round the clock. All that can be managed on the Samsung Galaxy Tab S2 tablet interface says the Irish firm. Medtronic senior vice president and Medtronic pain therapies president Marshall Stanton said that the Intellis platform combines cutting edge hardware with optimal therapy through the Evolve workflow to provide personalized, long-term pain relief. Stanton added: Medtronic is committed to addressing patient needs, so the Intellis platform was designed based on what is most important to patients and physicians. We considered the entire patient journey - startin Continue reading >>

Intellis | Comprehensive Pain Specialists

Intellis | Comprehensive Pain Specialists

CPS is the first in nation to offer the new next generation Medtronic Spinal Cord Stimulator for long-term management of chronic pain Brentwood, Tenn. [Oct. 13, 2017] Comprehensive Pain Specialists (CPS) is the first and only in the country to offer the Intellis platform, including the worlds smallest implantable spinal cord stimulator (SCS) for the management of certain types of chronic intractable pain. Chronic pain is a debilitating condition that can negatively impact all aspects of a persons life relationships, work productivity and activities of daily living, yet it remains under-recognized and undertreated.1 Given the national crisis involving opioid abuse, its more important than ever for patients suffering from chronic pain to have access to new non-opioid treatment options. At CPS, we are part of the solution, says Dr. Peter Kroll, chief executive officer and chief medical officer. We believe in responsible medication management and interventional modalities. There is no one-size-fits-all approach to managing pain. Its more important than ever for CPS to offer an effective, long-term, non-opioid solution; the availability of the Intellis spinal cord stimulator should offer new hope to patients struggling with debilitating pain. Back problems are one of the top 10 most expensive medical conditions, with an estimated 30 percent of the 300,000 patients annually that undergo lumbosacral spine procedures developing chronic intractable pain.1 Medtronic neurostimulation therapy for chronic pain uses an SCS system, which is a medical device placed under a patients skin to deliver mild electrical impulses through a lead implanted in the epidural space to block pain signals from going to the brain. Neurostimulation has been proven to provide effective long-term pain re Continue reading >>

Spinal Cord Stimulation Market Grows As Way To Treat Chronic Pain

Spinal Cord Stimulation Market Grows As Way To Treat Chronic Pain

Published 10:18 AM ET Thu, 29 March 2018 Connie Hanafy hikes with her daughter Marley. Hanafy was hardly able to walk until she received Medtronic's Intellis spinal cord stimulator. In less than a year, Connie Hanafy went from hiking and rollerskating with her daughters to hardly being able to walk. She had a benign tumor removed from her right leg in January 2017. For months after, she felt pain that didn't make sense. It wasn't typical post-procedure aches. It was a sharp, stabbing, throbbing and crushing feeling rolled up into one. "Before all of this happened, I was an extremely active person. I would hike all the time and was always doing things with my children," Hanafy said. "I was always outside and very outdoorsy. When this happened, it was a huge setback." The 32-year-old hospice worker from New Jersey was diagnosed with complex regional pain syndrome, a chronic condition that can develop after an injury or surgery. She tried treatments like steroid injections, nerve blocks and physical therapy, but the pain continued to worsen. Her only other option was opioid pain pills, but she refused to take them and risk slipping into addiction. By November, she just wanted her leg amputated. Dr. Youssef Josephson of The Pain Management Center in New Jersey suggested she try Intellis, a spinal cord stimulator. The device emits electrical pulses to help treat pain. The Food and Drug Administration had approved Intellis only a few months earlier. It's the latest system from Medtronic , the company that created the spinal cord stimulation market. It's one the medical device maker hopes will better help more patients and turn its performance in the category. Once the market leader, Medtronic ceded ground to rivals, just as the opioid epidemic was putting more focus on alter Continue reading >>

More in diabetes